Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. Issue 11 (10th April 2022)

• Record Type: Journal Article
• Authors: Li, Xiao-Yun; Luo, Dong-Hua; Guo, Ling; Mo, Hao-Yuan; Sun, Rui; Guo, Shan-Shan; Liu, Li-Ting; Yang, Zhen-Chong; Yang, Jin-Hao; Qiu, Fang; Sun, Xue-Song; Wang, Pan; Liu, Qing; Li, Ji-Bin; Tang, Qing-Nan; Lin, Chao; Yang, Qi; Liu, Sai-Lan; Liang, Yu-Jing; Jia, Guo-Dong; Wen, Dong-Xiang; Guo, Chun-Yan; Yan, Jin-Jie; Zhao, Chong; Chen, Qiu-Yan; Tang, Lin-Quan; Mai, Hai-Qiang
• Is Part Of: Journal of clinical oncology. Volume 40:Issue 11(2022)
• Page Start: 1163
• Page End: 1173
• Publication Date: 2022-04-10
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.21.01467
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : PURPOSE: Cumulative doses of 200 mg/m 2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority of a two-cycle 100 mg/m 2 concurrent DDP regimen over three-cycle in patients with low-risk LA-NPC with pretreatment Epstein-Barr virus DNA levels < 4, 000 copies/mL. PATIENTS AND METHODS: Eligible patients were randomly assigned 1:1 to receive two cycles or three cycles concurrent DDP-based chemoradiotherapy. The primary end point was 3-year progression-free survival (PFS). The secondary end points included overall survival, distant metastasis-free survival, locoregional relapse-free survival, etc. RESULTS: Between September 2016 and October 2018, 332 patients were enrolled, with 166 in each arm. After a median follow-up of 37.7 months, the estimated 3-year PFS rates were 88.0% in the two-cycle group and 90.4% in the three-cycle group, with a difference of 2.4% (95% CI, –4.3 to 9.1, P noninferiority = .014). No differences were observed between groups in terms of PFS, overall survival, and the cumulative incidences of locoregional relapse and distant metastasis. Patients in the three-cycle group developed significantly more grade 3-4 mucositis (41 [24.8%] v 25 [15.1%]), hyponatremia (26 [15.8%] v 14 [8.4%]), and dermatitis (9 [5.5%] v 2 [1.2%]). The overall all-grade and grade 3-4 toxicity burdens were heavier in three-cycle group (T-scores, 12.33 v 10.57, P < .001 for all grades; 1.76 v 1.44, P = .05 for grade 3-4). Patients in the three-cycle group also showed more all-grade hearing impairment, dry mouth and skin fibrosis, and impaired long-term quality of life. CONCLUSION: Intensity-modulated radiotherapy plus two cycles of concurrent 100 mg/m 2 DDP could be an alternative treatment option for patients with low-risk LA-NPC. Abstract :